Origo Biopharma Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 10

Employees

  • Latest Deal Type
  • M&A

Origo Biopharma General Information

Description

Developer of organ-restricted drugs intended to address unmet medical needs related to cancer and fibrosis. The company's drug addresses health disorders related to TGF-β signaling dysfunction, cancer, and fibrosis, enabling people to get cures from devastating medical conditions.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Parque Empresarial de Touro
  • Parcelas 26-27, Fonte Díaz
  • 15822 A Coruna
  • Spain
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Vertical(s)
Corporate Office
  • Parque Empresarial de Touro
  • Parcelas 26-27, Fonte Díaz
  • 15822 A Coruna
  • Spain

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Origo Biopharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 26-Oct-2021 Completed Generating Revenue
1. Seed Round 07-Jul-2020 Completed Clinical Trials - Phase 1
To view Origo Biopharma’s complete valuation and funding history, request access »

Origo Biopharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Origo Biopharma Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Asabys Partners Venture Capital Minority
XesGalicia Venture Capital Minority
To view Origo Biopharma’s complete investors history, request access »

Origo Biopharma FAQs

  • When was Origo Biopharma founded?

    Origo Biopharma was founded in 2017.

  • Where is Origo Biopharma headquartered?

    Origo Biopharma is headquartered in A Coruna, Spain.

  • What is the size of Origo Biopharma?

    Origo Biopharma has 10 total employees.

  • What industry is Origo Biopharma in?

    Origo Biopharma’s primary industry is Biotechnology.

  • Is Origo Biopharma a private or public company?

    Origo Biopharma is a Private company.

  • What is Origo Biopharma’s current revenue?

    The current revenue for Origo Biopharma is .

  • How much funding has Origo Biopharma raised over time?

    Origo Biopharma has raised $2.59M.

  • Who are Origo Biopharma’s investors?

    Asabys Partners and XesGalicia have invested in Origo Biopharma.

  • When was Origo Biopharma acquired?

    Origo Biopharma was acquired on 26-Oct-2021.

  • Who acquired Origo Biopharma?

    Origo Biopharma was acquired by Agomab Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process